Notifications
Clear all
Topic starter
09/06/2026 11:12 pm
TL;DR: Life sciences metadata is the chain of custody that regulators use to judge whether trial data is attributable, auditable and defensible, according to Collibra, and weak lineage can unravel even strong efficacy results. Metadata governance is not a documentation layer; it is the control surface that turns clinical data into evidence.
NHIMG editorial — based on content published by Collibra: metadata governance in life sciences and why it underpins data trust
By the numbers:
- Only 5.7% of organisations have full visibility into their service accounts.
- 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools.
- 90% of IT leaders say properly managing NHIs is essential for a successful zero-trust implementation.
Questions worth separating out
Q: How should life sciences teams govern metadata for regulated submissions?
A: They should treat metadata as regulated evidence, not administrative detail.
Q: Why does metadata matter as much as the data itself in pharma and biotech?
A: Because the regulator is not only judging what the numbers say.
Q: What breaks when clinical data has weak lineage and audit trails?
A: The organisation loses evidentiary continuity.
Practitioner guidance
- Map regulated data to its proof trail Define the minimum metadata set for each clinical or research record, including source, timestamp, system of origin, editor identity and change history.
- Tie metadata stewardship to named owners Assign a business owner and technical steward for each critical metadata domain, with explicit responsibility for validation, exception handling and retention.
- Align access controls with validated system boundaries Review whether the systems that generate or transform regulated data are themselves inside approved access, logging and change-control boundaries.
What's in the full article
Collibra's full article covers the operational detail this post intentionally leaves for the source:
- FDA and ICH context for why metadata functions as chain of custody in regulated submissions
- How ALCOA+ maps to provenance, audit trails and defensible evidence handling
- Operational steps for capturing and governing system identifiers, timestamps and record lineage
- Why metadata quality affects review cycles, submission friction and public trust
👉 Read Collibra's analysis of metadata governance in life sciences →
Metadata governance in pharma and biotech: what teams must prove?
Explore further
10/06/2026 1:28 am
Metadata governance is the control plane for regulated evidence. In life sciences, the question is not whether the dataset contains the right numbers but whether the organisation can prove where those numbers came from and who touched them. FDA 21 CFR Part 11 and ALCOA+ both reflect the same underlying governance requirement: data must remain attributable across its full lifecycle. Practitioners should treat metadata as the proof layer for regulated identity and access, not as an administrative afterthought.
A few things that frame the scale:
- Only 5.7% of organisations have full visibility into their service accounts, according to Ultimate Guide to NHIs , Key Research and Survey Results.
- 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools.
A question worth separating out:
Q: Who should own metadata governance in regulated life sciences programmes?
A: Ownership should sit with a named business steward and a technical steward, because metadata is both operational and evidentiary. The business owner defines what must be proven, while the technical owner ensures those fields are captured, protected and auditable across the lifecycle.
👉 Read our full editorial: Metadata governance in life sciences is now a regulatory control
